Latest Breaking News On - Mybiotics pharma - Page 4 : comparemela.com

Ferring, Israel's MyBiotics look to microbiome to treat vaginal infection

Redirecting to Ferring, Rebiotix and MyBiotics Collaborate to Develop Live Microbiome-Based Therapeutics in Reproductive Medicine and Maternal Health

Ferring, Rebiotix and MyBiotics Collaborate to Develop Live Microbiome-Based Therapeutics in Reproductive Medicine and Maternal Health Ferring Pharmaceuticals, Rebiotix Inc., a Ferring Company, and MyBiotics Pharma Ltd. today announced a multi-year strategic collaboration to develop live microbiota-based biotherapeutics to address bacterial vaginosis, a common vaginal infection among women of reproductive age linked to increased risk of miscarriage and complications for pregnancy and fertility.1,2,3 The collaboration is an important step forward in harnessing the power of the human microbiome in this area of women’s health. Currently bacterial vaginosis is treated with antibiotics, which can disrupt the vaginal microbiome, and it’s common for bacterial vaginosis to return following treatment.4 The aim of a microbiota-based treatment would be to reduce the need for antibiotic use and provide a long-term treatment solution.

Ferring, Rebiotix and MyBiotics Collaborate to Develop Live Microbiome-Based Therapeutics in Reproductive Medicine and Maternal Health

MyBiotics Pharma reçoit un investissement du japonais Mii Fund, innovateur dans le domaine de la dermatologie.

MyBiotics Pharma Receives Investment from Mii Fund, an Innovator in the Field of Dermatology

MyBiotics Pharma Receives Investment from Mii Fund, an Innovator in the Field of Dermatology USA - English News provided by Share this article Share this article REHOVOT, Israel, Feb. 3, 2021 /PRNewswire/  MyBiotics Pharma, a microbiome therapeutics company, announced today that it has received an investment from Mii Fund, a partnership with Maruho Co. Ltd., Japan s preeminent leader in dermatology. MyBiotics will use the funds to advance its microbiome therapeutics pipeline and continue to enhance its unique microbiome platform technologies. In addition, the company is initiating a development program in the field of skin microbiome, leveraging the support of the Mii Fund & Lab, and the relationship with Maruho Co. Ltd, a leading market player in the dermatology market.